Sinil Pharmaceutical Co Ltd banner
S

Sinil Pharmaceutical Co Ltd
KOSDAQ:012790

Watchlist Manager
Sinil Pharmaceutical Co Ltd
KOSDAQ:012790
Watchlist
Price: 6 480 KRW 2.05% Market Closed
Market Cap: ₩77.7B

Sinil Pharmaceutical Co Ltd
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sinil Pharmaceutical Co Ltd
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
S
Sinil Pharmaceutical Co Ltd
KOSDAQ:012790
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Non-Reccuring Items
₩79.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
17%
SK Biopharmaceuticals Co Ltd
KRX:326030
Non-Reccuring Items
₩597.3m
CAGR 3-Years
-48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Non-Reccuring Items
-₩3B
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
14%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Non-Reccuring Items
-₩50.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
27%
C
Caregen Co Ltd
KOSDAQ:214370
Non-Reccuring Items
₩0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sinil Pharmaceutical Co Ltd
Glance View

Market Cap
77.7B KRW
Industry
Pharmaceuticals

Sinil Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceutical products. The company is headquartered in Chungju, Chungcheongbuk-Do. The Company’s products consist of antihyperlipidemic agents, antitussives, expectorants, anti-antipyretic agents, analgesic agents, inflammatory agents, dermatological treatments, chemotherapeutic agents, antihistamines, antihypertensives and mixed vitamins, among others. The company also engages in the leasing of real estate.

Intrinsic Value
6 666.58 KRW
Undervaluation 3%
Intrinsic Value
Price ₩6 480
S

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett